ZyVersa Therapeutics, Inc. Announces Reverse Stock Split and Increase in Authorized Shares of Common StockGlobeNewsWire • 11/30/23
ZyVersa Therapeutics Reports Third Quarter 2023 Corporate Update and Financial ResultsGlobeNewsWire • 11/14/23
ZyVersa Therapeutics Announces Article Published in Peer-Reviewed Biomedical Journal Demonstrating That NLRP3 Inflammasome Inhibition Attenuates Inflammatory Bowel Disease Symptoms in Animal ModelGlobeNewsWire • 11/09/23
ZyVersa Therapeutics Announces Article in Peer-Reviewed Journal, Ecotoxicology and Environmental Safety, Linking Air Pollution with Development and Progression of Chronic Kidney Disease That Can Be Attenuated by Inhibiting Inflammasome NLRP3 ActivationGlobeNewsWire • 11/06/23
ZyVersa Therapeutics Announces Publication in Molecular Neurobiology Reinforcing Data Demonstrating That Inflammasome ASC Inhibitor IC 100 Attenuates the Inflammatory Response Causing Neuronal Damage in Multiple Sclerosis Model, Potentially Providing NeuroprotectionGlobeNewsWire • 11/01/23
ZyVersa Therapeutics Announces Research Published in the Peer-Reviewed Journal Diabetes Reinforcing IC 100's Rationale for Inhibiting ASC to Attenuate Damaging Inflammation Associated with Serious Conditions Such as Obesity-related Heart DiseaseGlobeNewsWire • 10/25/23
ZyVersa Therapeutics Announces a Publication in the Peer-Reviewed Journal, Aging, Linking Inflammasome NLRP3 Activation with Age-Related Structural Changes in the Kidney and Reduced Kidney FunctionGlobeNewsWire • 10/18/23
ZyVersa Therapeutics Announces Peer-Reviewed Publication in Nature Reviews Nephrology Substantiating VAR 200's Rationale for Mediating Transport of Cholesterol and Lipids Out of Kidney Cells to Attenuate Progression of Kidney DiseaseGlobeNewsWire • 10/11/23
ZyVersa Therapeutics Announces New Peer-Reviewed Publication Reinforcing the Rationale for Inhibiting ASC Specks with IC 100 to Attenuate Spread of Inflammation into Surrounding TissuesGlobeNewsWire • 10/04/23
ZyVersa Therapeutics' CEO, Stephen C. Glover to Participate in Panel at the BioFlorida Conference Discussing Inflammation and its Impact on Numerous DiseasesGlobeNewsWire • 09/27/23
ZyVersa Therapeutics Announces Research Published in The Journal of Clinical Investigation Reinforcing IC 100's Rationale for Inhibiting ASC Specks to Attenuate Spread of Inflammation into Surrounding TissuesGlobeNewsWire • 09/22/23
ZyVersa Therapeutics Announces Research Published in Frontiers in Immunology Reinforcing IC 100's Rationale for Inhibiting Multiple Inflammasomes to Control Inflammation in Various Inflammatory DiseasesGlobeNewsWire • 09/12/23
ZyVersa Therapeutics Reports Second Quarter 2023 Corporate and Financial ResultsGlobeNewsWire • 08/21/23
ZyVersa Therapeutics Announces Publication in the Journal, Hepatology, Highlighting the Role of NLRP3 Inflammasome-Mediated IL-18 in Development of Liver FibrosisGlobeNewsWire • 07/15/23
ZyVersa Therapeutics Announces Publication in the Journal Circulation That Demonstrates the Role of Inflammasome Activation in Hypertrophic Heart Disease Induced by Mechanical StressGlobeNewsWire • 07/10/23
European Patent Granted for ZyVersa Therapeutics' Lead Asset, Cholesterol Efflux Mediator™ VAR 200 for Use in Patients with Diabetic Nephropathy/Diabetic Kidney DiseaseGlobeNewsWire • 07/07/23
ZyVersa Therapeutics Announces Publication in Clinical Immunology Demonstrating Association Between Renal NLRP3 Inflammasome Activation and Lupus Nephritis Disease ActivityGlobeNewsWire • 06/28/23
ZyVersa Therapeutics Announces a Publication in Journal of the American Heart Association Linking NLRP3 Inflammasomes with Calcification in Arteries of Patients with Peripheral Arterial Disease (PAD)GlobeNewsWire • 06/20/23
ZyVersa Therapeutics Publishes New White Paper Detailing the Critical Role of Inflammasome ASC in Inflammatory Diseases, and Its Potential as a Therapeutic TargetGlobeNewsWire • 06/13/23
European Patent Office to Grant ZyVersa Therapeutics' Patent Application for Cholesterol Transport Mediator™ VAR 200 for Use in Patients with Diabetic Nephropathy/Diabetic Kidney DiseaseGlobeNewsWire • 06/06/23
ZyVersa Therapeutics Announces a Publication in Frontiers in Medicine Showing Direct Inflammasome Activation in Children with Juvenile Idiopathic ArthritisGlobeNewsWire • 05/25/23